Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...
Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.
Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...
Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.
Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...
Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...
Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker. Julie ...
The University of Electro-Communications (UEC) proudly announces the release of the January 2025 issue of its Research and Innovation newsletter. This edition highlights cutting-edge research and ...
EQS-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Personnel Takeda Pharmaceutical Company Limited: Julie Kim Will ...
Not for Distribution to U.S. News Wire Services or Dissemination in the United States Clean Energy Transition Inc. is pleased to announce that Management has posted a short Investor Update to the ...
Myriad Uranium Corp. announces that it has granted an aggregate of 225,000 incentive stock options to certain of its consultants and an aggregate of 1,095,000 restricted share units to certain of its ...
Experts believe Griffin wants to only have the case be argued at the state level, as the State Supreme Court has a 5-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback